Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OVID
SellHot AirOvid Therapeutics Inc. · Healthcare · United States · $547M · Avg Vol: $4M/d
COMPANY DESCRIPTION
Ovid Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for rare neurological diseases, with a particular focus on genetic epilepsies and other brain disorders. The company's strategy involves targeting orphan conditions with high unmet medical needs, which could lead to accelerated regulatory pathways and market exclusivity upon approval. Ovid's competitive differentiation comes from its proprietary drug discovery platform and strategic partnerships aimed at advancing promising pipeline candidates.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 208.4M | 1.5M | 0.4M | 0.6M | 7.3M | -56.8% | 1.6M | 0.8M | 0.2M | -82.5% |
| EPS | 1.78 | -0.29 | -0.28 | -0.14 | -0.23 | — | -0.21 | -0.38 | -0.40 | — |
| Shares | 70.4M | 186.6M | 186.6M | 186.6M | 130.2M | +85.0% | — | — | — | — |
| Debt | 0 | 16.5M | 16.0M | 14.8M | 13.4M | -6.7% | 12.7M | — | — | — |
| Equity | 179.7M | 132.3M | 87.8M | 68.2M | 130.7M | -7.7% | — | — | — | — |
| Op CF | 118.6M | -55.2M | -45.8M | -56.0M | -38.3M | — | -54.8M | — | — | — |
| Inv CF | -1.8M | -87.9M | -2.6M | 54.6M | -49.9M | — | — | — | — | — |
| Fin CF | 0.9M | 0.2M | 30.5M | 0.6M | 75.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OVID are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OVID | Ovid Therapeutics Inc.(you) | $547M | 35 | Sell |
| ARTV | Artiva Biotherapeutics, Inc. | $542M | 37 | Hold |
| GYRE | Gyre Therapeutics, Inc. | $699M | 34 | Sell |
| SGMT | Sagimet Biosciences Inc. | $656M | 32 | Sell |
| ARVN | Arvinas, Inc. | $592M | 40 | Hold |
| NGNE | Neurogene Inc. | $732M | 34 | Sell |
| CTNM | Contineum Therapeutics, Inc. | $641M | 30 | Sell |
| ASMB | Assembly Biosciences, Inc. | $694M | 31 | Sell |
| OABI | OmniAb, Inc. | $650M | 40 | Hold |
| PRLD | Prelude Therapeutics Incorporated | $437M | 29 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%